Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients ...
In urothelial bladder cancer, increased T cell infiltration has been correlated with longer patient survival. Previous clinical studies with an FGFR inhibitor, rogaratinib, demonstrated that the ...
Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...